• 265 days Could Crypto Overtake Traditional Investment?
  • 270 days Americans Still Quitting Jobs At Record Pace
  • 272 days FinTech Startups Tapping VC Money for ‘Immigrant Banking’
  • 275 days Is The Dollar Too Strong?
  • 275 days Big Tech Disappoints Investors on Earnings Calls
  • 276 days Fear And Celebration On Twitter as Musk Takes The Reins
  • 278 days China Is Quietly Trying To Distance Itself From Russia
  • 278 days Tech and Internet Giants’ Earnings In Focus After Netflix’s Stinker
  • 282 days Crypto Investors Won Big In 2021
  • 282 days The ‘Metaverse’ Economy Could be Worth $13 Trillion By 2030
  • 283 days Food Prices Are Skyrocketing As Putin’s War Persists
  • 285 days Pentagon Resignations Illustrate Our ‘Commercial’ Defense Dilemma
  • 286 days US Banks Shrug off Nearly $15 Billion In Russian Write-Offs
  • 289 days Cannabis Stocks in Holding Pattern Despite Positive Momentum
  • 290 days Is Musk A Bastion Of Free Speech Or Will His Absolutist Stance Backfire?
  • 290 days Two ETFs That Could Hedge Against Extreme Market Volatility
  • 292 days Are NFTs About To Take Over Gaming?
  • 293 days Europe’s Economy Is On The Brink As Putin’s War Escalates
  • 296 days What’s Causing Inflation In The United States?
  • 297 days Intel Joins Russian Exodus as Chip Shortage Digs In
  1. Home
  2. Markets
  3. Other

After The Crash*, Part 2: Digital And Regenerative Medicine

For most people, the doctor visit hasn't changed in decades. Same physical waiting rooms, same paper forms to fill out, same slow, expensive tests and marginally-effective, maximally-invasive treatments. But that's about to change, as a wave of new technologies drag medicine into the 21st century. Among the most interesting:

Digitized research. Instead of laboriously searching for medicines in the natural world, today's scientists use algorithms to design thousands of chemicals and “labs on a chip” to test them quickly and accurately. The result: processes that used to take years now take months, weeks, or days, resulting in a tidal wave of powerful new drugs in various stages of development.

Cheap, fast tests. Many of today's medical tests require the culturing of cells in a lab to get enough genetic material to analyze. For example, testing for sepsis (a common, extremely dangerous infection) might take three days and cost $2,000. But several start-ups are introducing advanced molecular diagnostic tools that can test for sepsis in few hours for less than $100. Lots of other tests are being simplified in this way.

Synthetic biology. The emerging ability to mix and match genetic material -- or build it from scratch -- to create new life forms is allowing researchers to, for instance, harness specially-designed bacteria to mass produce next-generation antibiotics, vaccines and cancer drugs.

Genomics for the masses. Sequencing the first human genome required $3 billion and 13 years. 15 years later, the $1,000, 24-hour genome is in sight. The possibilities opened up by widely-available genomics include the ability to determine which cancer drug will work on which cancer, something today's oncologists can only guess at.

Stem cells. Undifferentiated cells that can become anything from neurons to entire new organs were discovered more than three decades ago. But only in the past couple of years has it become possible to make them follow instructions. Scientists are now growing cartilage to repair damaged joints that previously required surgery, while others are creating entire new organs for transplantation.

Trillion-dollar market
Healthcare is one of the two or three biggest global markets, encompassing everything from large pharmaceutical companies and medical device makers to hundreds of start-ups bringing potentially disruptive products to market. So even relatively small niches are potential billion-dollar businesses.

That means a couple of things. First, lots of action. Big companies will be buying out emerging players and new breakthroughs will be announced by labs around the world on a daily basis. So nothing is certain and everything is in flux, which pretty much defines the intellectual challenge of a hot industry. Second, the breakthrough technologies all sound spectacular but, based on the history of previous paradigm shifts, only a tiny minority will ever make it to market. So skepticism is more important here than in normal sectors.

So the best way to approach this kind of industry is to 1) never believe anything you hear until real proof accompanies the wild assertions, 2) diversify across sub-sectors to moderate their volatility, and 3) identify and seek the help of experts. Here's a (very partial) list of biotech related news feeds and newsletters:

FierceBiotech
Prohost Biotechnology
?Prudent Biotech Newsletter
BioInvest
BioPortfolio
Biotech Newsletters - Stockfocus.com
Currin Biotech Investment Newsletter
Biotechnology News - ScienceDaily

And a few representative articles:

Next-Generation Genomics, Precision Medicine to Top $100B
Luminex to Acquire Nanosphere for 69% premium to previous day's close
A Pure Regenerative Medicine Play
Silicon Valley elites look to live forever

*Most of these stocks will tank in the coming equities bear market. At the bottom -- after the crash -- potential ten-baggers will be common. So get up to speed on them now. For the previous article in this series, see After The Crash, Part 1: Solar Stocks

 

Back to homepage

Leave a comment

Leave a comment